Related Experiment Video
Updated: Jun 21, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
The Effects of ML385 on Head and Neck Squamous Cell Carcinoma: Implications for NRF2 Inhibition as a Therapeutic
Eun-Jeong Jeong1, Jong Joong Choi1, Sun Young Lee1
1Department of Otorhinolaryngology, Myunggok Medical Research Institute, Konyang University Hospital, Konyang University College of Medicine, Daejeon 35365, Republic of Korea.
Abstract:
Head and neck squamous cell carcinoma (HNSCC) affects squamous cells in the head and neck region and is currently ranked as the sixth most common cancer worldwide. NF-E2-related factor 2 (NRF2) plays a crucial role in cellular protection and defence mechanisms and NRF2 over-expression has been linked to various cancers; however, its role in the response of HNSCC cells remains elusive. We investigated the effects of ML385, a selective NRF2 inhibitor, on HNSCC to understand the underlying molecular mechanisms, and to assess the potential of ML385 as a therapeutic agent. We treated HNSCC cell lines with ML385 and observed a significant reduction in the expression of NRF2 and its downstream target, heme oxygenase-1 (HO-1), using Western blotting. We evaluated its effects on various cellular processes, including cell proliferation, cloning, migration, and wound healing, in HNSCC cell lines. ML385 treatment substantially reduced NRF2 expression, promoting a decrease in the investigated cellular activities. Additionally, we examined changes in the expression of cell-cycle-related proteins and found that ML385 induced cell cycle arrest at the G1/S phase in HNSCC cell lines. Our findings suggest that ML385 can regulate cell cycle progression, inhibit HNSCC growth, and have potential as a therapeutic agent for HNSCC.
Insights
ML385, a selective NRF2 inhibitor, significantly reduces head and neck squamous cell carcinoma (HNSCC) growth by inhibiting NRF2 expression and inducing cell cycle arrest. This suggests ML385
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Head and neck squamous cell carcinoma (HNSCC) is a globally prevalent cancer.
- The role of NF-E2-related factor 2 (NRF2) in HNSCC response is not fully understood, despite its link to other cancers.
- NRF2 is a key regulator of cellular protection and defense mechanisms.
Purpose of the Study:
- To investigate the effects of the NRF2 inhibitor ML385 on HNSCC.
- To elucidate the molecular mechanisms underlying ML385's action in HNSCC.
- To assess the therapeutic potential of ML385 for HNSCC treatment.
Main Methods:
- HNSCC cell lines were treated with ML385.
- Western blotting was used to assess NRF2 and heme oxygenase-1 (HO-1) expression.
- Cellular processes including proliferation, cloning, migration, and wound healing were evaluated.
- Cell cycle-related protein expression was analyzed to determine cell cycle phase distribution.
Main Results:
- ML385 treatment significantly reduced NRF2 and HO-1 expression in HNSCC cells.
- ML385 inhibited HNSCC cell proliferation, cloning, migration, and wound healing.
- ML385 induced cell cycle arrest at the G1/S phase in HNSCC cell lines.
Conclusions:
- ML385 effectively inhibits NRF2 signaling in HNSCC.
- ML385 demonstrates potential as a therapeutic agent by regulating cell cycle progression and inhibiting HNSCC growth.
- Targeting NRF2 with ML385 offers a promising strategy for HNSCC treatment.
More Related Videos
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:11Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...